Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update

Performance

52-Week Range 18.9% below 52-week high

162.23

105.8852W Low 200.0052W High

1 Week 5.1% below 1-week high

141.001W Low 170.891W High

Belite Bio, Inc - American Depositary Shares (BLTE) traded between $105.88 and $200.00 over the past 52 weeks and last traded at $162.23, 18.9% below its 52-week high. Over the past week it ranged between $141.00 and $170.89.

Past 12 Months

+5.2%

+6.8%

-2.4%

+8.2%

+1.9%

+46.4%

1W +$8.04

1M +$10.36

3M -$4.05

6M +$12.28

YTD +$2.96

1Y +$51.41

BLTE was +46.4% over the past year, +8.2% over six months, +1.9% year to date, +5.2% in the last week.

12 Months vs Market

BLTE

+46.4%

DIA

+8.1%

SPY

+9.8%

QQQ

+8.5%

IWM

+13.3%

Over the past 12 months BLTE returned +46.4% versus DIA (Dow) +8.1%, SPY (S&P 500) +9.8%, QQQ (Nasdaq 100) +8.5% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.29× 3-mo avg

Today 54,920 3-mo avg 187.5K

272.5K

176.7K

187.5K

197.9K

YTD

191.0K

198.2K

BLTE most recently traded 54,920 shares against a 3-month average daily volume of 187.5K.

More News

November 12, 2026

Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results

November 05, 2026

Belite Bio Announces Uplisting to the Nasdaq Global Select Market

October 19, 2026

Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1

October 14, 2026

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

October 01, 2026

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

September 28, 2026

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

September 08, 2026

Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease ↗

September 03, 2026

Belite Bio to Participate in Four Upcoming Investor Conferences

September 01, 2026

Belite Bio to Host Virtual Commercial Day on September 2, 2026

August 24, 2026

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

August 21, 2026

Belite Bio Q2 Earnings Call Highlights ↗

August 13, 2026

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Full Transcript: Belite Bio Q2 2026 Earnings Call ↗

August 13, 2026

Via Benzinga

August 12, 2026

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

August 11, 2026

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

August 06, 2026

Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases ↗

July 22, 2026

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

July 20, 2026

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

July 15, 2026

Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗

July 09, 2026

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

July 06, 2026

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

July 06, 2026

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

June 12, 2026